Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. - Wikidata - wikimedia - TriplyDB

Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.

Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.

http://www.wikidata.org/entity/Q36067677

about

Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective.Technical aspects of radiation therapy for anal cancer.Fat composition changes in bone marrow during chemotherapy and radiation therapy.Spatial mapping of functional pelvic bone marrow using FLT PET.Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therap Feasibility study of pelvic helical IMRT for elderly patients with endometrial cancer Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties.Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases.Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume h Internal target volume for post-hysterectomy vaginal recurrences of cervical cancers during image-guided radiotherapy.[(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients.Intensity-Modulated Radiation Therapy Versus 3D Conformal Radiotherapy for Postoperative Gynecologic Cancer: Are They Covering the Same Planning Target Volume?Radiation therapy oncology group gynecologic oncology working group: comprehensive results Radiation treatment in older patients: a framework for clinical decision making.Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective.Image-guided radiotherapy and -brachytherapy for cervical cancer.Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy.Proton radiotherapy for gynecologic neoplasms.The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature.Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer.Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes.Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer Dose-volume analysis of predictors for chronic gastrointestinal complications in patients with cervical cancer treated with postoperative concurrent chemotherapy and whole-pelvic radiation therapy.Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy.Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer.Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma.The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation.Managing an Older Adult with Cancer: Considerations for Radiation Oncologists.Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion

P2860

Q30235359-66D452F1-2FFE-4B02-AAA8-F5DEF8FFB63C Q33820797-CDA733D5-7F2C-49BB-B502-05F8D79B989E Q34156572-EB4B0933-44B5-4D95-9FBF-55F63E02631C Q34169627-80E01795-F31D-44A2-9CE6-735E6B9C9486 Q34434263-88E2E8D9-8AC3-4C55-A717-14158A43E3AE Q34572108-95B3A59C-48D5-4CB6-90AA-187CCC184201 Q35868207-11F1D770-A7E4-4042-8A36-4EFC807E3135 Q35945537-E4CEB531-26FA-4D24-868F-29B201860123 Q36010000-0BE24804-B419-44DE-989D-3FAEA2915B60 Q36514451-564C2A4F-CEC4-46C8-9E8B-A8CF73D50BE4 Q36609751-F4B02C81-AEE9-4610-86D7-B6D2317A3C24 Q36631978-3206571C-2C32-4316-B127-7CD1B4FFC41A Q36730351-036DD0E2-27A6-4B94-9E88-2C6E15C0C460 Q36925147-4765A457-6D20-437B-895D-C94AF52E7B1D Q37705029-3F242B43-8575-4F1E-B08A-D211FB7EF5F2 Q38225041-58647572-F3D7-469E-93D9-4B705E418764 Q38411239-A58A3386-EA32-4EC2-80A8-F43A7218B461 Q38916902-05C964E7-4A77-4767-9AD0-A43681693280 Q38921612-A15E8497-A0FF-4657-89D2-0A2AECDF0500 Q39132126-487DAE3B-21DA-4629-8BC2-AC6D8C93CEB1 Q39177680-8605FEB6-B042-4216-9093-BC3F60B9B860 Q40733375-E38EC8CB-3C60-4C79-88A2-32D6FA5F3AB8 Q41039878-C62CA57C-C92A-4937-92F4-832C85935262 Q41670890-0B5880BD-76A3-459D-A257-33B0F644FDF1 Q42358784-34FE7D51-6B02-49E9-9E85-62E4853C7D59 Q46775347-FFC2D010-A81D-41EE-9A16-EF1F871D0DEF Q47129479-4B020E04-AD5A-4402-8BB8-9ABB40C265D0 Q47161713-925C75BC-AB68-443B-8539-04412BFD6D6E Q48117888-8DCC3F36-930F-46B5-A019-BAA26A960FFC Q48128980-DD158462-B922-404B-A9FB-7D696A6877A4 Q58724829-445B7EAA-67D9-4FE3-B95E-CCF06D8C5472

P2860

Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.

http://www.wikidata.org/entity/Q36067677

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@ast

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@en

type

label

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@ast

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@en

prefLabel

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@ast

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@en

P1433

Q36067677-CB3BA937-89D8-4CC6-B3DE-BDB870416F95

P1476

Q36067677-4A1447B5-10BB-494A-821E-2BE66E25D2BD

P2093

Q36067677-212A9529-DEB6-494A-BA50-981C599328C5

Q36067677-422DF12D-6CB3-49BF-B802-E21EA8E78BD2

Q36067677-504638B3-49D9-45AE-9553-D2D19A3F79BB

Q36067677-61B226D5-7240-4953-9378-E6A5F1353A34

Q36067677-65E9A162-EDEA-4536-BD55-37F649A95CF3

Q36067677-85F2849E-6DDF-4816-B42C-DF71AAA4451D

Q36067677-91AD386D-11C4-47E2-A2C3-D39B0FE227FB

Q36067677-9A0717AB-736B-4519-B04C-746C2B1AB9F6

Q36067677-9DF6A82B-1C59-4DA7-9A8D-32E5D7EDE6C7

Q36067677-AB711A70-8AFB-44F3-B6F7-312D58BA5DCB

P2860

Q36067677-1702F891-6151-4051-8E90-ACD25E916C09

Q36067677-1AC91EF5-5C6B-4AEE-92BD-EA8049531870

Q36067677-566C7CD1-FDF9-4D85-83AE-0913D7EDFAE1

Q36067677-65430C2C-1785-4DBB-BEA0-6E5D2855B8DF

Q36067677-6720AC8A-145D-4147-9294-3885F2256A16

Q36067677-701B4502-5CD4-4EAF-A0F1-73AB622D8E43

Q36067677-EF7CBA3D-8232-45A5-AD34-621D61D9E604

P304

Q36067677-D4FCD3B9-CDCE-40C6-9C03-CF0936D5A2AD

P31

Q36067677-DBAEB11B-F89A-499A-86C6-17638F591CC6

P356

Q36067677-D45224AA-E7C5-476E-A167-06344CB76688

P407

Q36067677-E7802F61-9285-4C18-9BCF-77FA8BB16E29

P433

Q36067677-2A39A7D5-8477-4728-A6C6-FD21F1FBC67A

P478

Q36067677-B485FD35-AD26-44BE-A831-C7D14B0CE59C

P577

Q36067677-DBDE2A48-21EA-4DCF-B5D1-6DAF6B077FEC

P5875

Q36067677-3D8249C2-B8AE-41DF-ABE3-19C068FF962B

P698

Q36067677-9DBE1113-0675-4487-902C-5E2AEB765EC8

P932

Q36067677-9FA89524-EFDB-4F3A-B8B7-4C4254E8B2C3

P356

J.IJROBP.2013.01.017

P1433

International Journal of Radiation Oncology Biology Physics

P1476

Hematologic toxicity in RTOG 0 ...... e IMRT for gynecologic cancer.

@en

P2093

Ann H Klopp

http://www.w3.org/2001/XMLSchema#string

Anuja Jhingran

http://www.w3.org/2001/XMLSchema#string

Brigitte E Miller

http://www.w3.org/2001/XMLSchema#string

David D'Souza

http://www.w3.org/2001/XMLSchema#string

Evangeline Hildebrandt

http://www.w3.org/2001/XMLSchema#string

Jennifer Moughan

http://www.w3.org/2001/XMLSchema#string

Jenny Nuanjing

http://www.w3.org/2001/XMLSchema#string

Lorraine Portelance

http://www.w3.org/2001/XMLSchema#string

Luis Souhami

http://www.w3.org/2001/XMLSchema#string

Mohammad R Salehpour

http://www.w3.org/2001/XMLSchema#string

P2860

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells.

Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.

Chemoradiotherapy for cervical cancer in 2010.

Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.

P304

83-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2013.01.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236198637

http://www.w3.org/2001/XMLSchema#string

P698

23582248

http://www.w3.org/2001/XMLSchema#string

P932

4572833

http://www.w3.org/2001/XMLSchema#string